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608Impact of HLA-DPB1 Haplotypes on Outcome of 10/10
Matched Unrelated Hematopoietic Stem Cell Donor
Transplants Depends on MHC-Linked Microsatellite
Polymorphisms
Florence Bettens,1 Jakob Passweg,2 Urs Schanz,3 Yves Chalandon,2 Dominik Heim,4
Tayfun G€ung€or,5 Georg Stussi,3 Grazia Nicoloso,6 Helen Baldomero,4 Alois Gratwohl,4
Jean-Marie Tiercy1,7Hematopoietic stem cell transplantation (HSCT) with HLA-A, -B, -C, -DRB1, -DQB1 allele matched (10 of
10) unrelated donors is still associated with a significant rate of posttransplantation complications. In order
to disclose additional immunogenetic factors, we analyzed the impact of HLA-DPB1 disparities and major
histocompatibility complex (MHC)-resident microsatellite polymorphisms in 246 HLA 10 of 10 matched
HSCT patients. First we showed that patients with more frequent/conserved HLA haplotypes had a higher
5-year survival (55% 6 18% versus 39% 6 18%, P 5 .021). In addition, DPB1 incompatibilities and 3 micro-
satellite alleles were associated with outcome. In a Cox regression model adjusting for European Blood and
Marrow Transplant (EBMT) risk score, T cell depletion, and year of treatment, HSCTwith a tumor necrosis
factor d (TNFd) 4/d5-positive donor was associated with increasedmortality (hazard ratio [HR]5 2.03; con-
fidence interval [CI] 1.25-3.31; P5.004), whereas the D6S510-184 allele was protective (HR5 0.44; CI 0.22-
0.87; P 5 .018). The 2 MHC-linked genetic donor factors, DPB1 mismatch (MM), and TNFd4/d5-positivity,
acted in synergy with the EBMT risk score with an always lower survival (HR 5 2.97; CI 1.27-6.92; P 5
.012). These data show that multiple MHC-linked genetic donor factors impact on outcome after unrelated
donor HSCT. Their additive and potentially divergent effects could explain previous discrepant results, par-
ticularly with respect to the role of HLA-DPB1 disparities. We conclude that HLA-DPB1 typing combined
with a simple TNFd microsatellite genotyping assay may significantly help in pretransplantation risk
assessment for graft-versus-host disease and mortality, particularly for patients with several potential 10
of 10 matched donors.
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With the increasing number of HLA-typed volun-
teer donors in the many donor registries worldwide,
identification of amatched unrelated donor has become
reality for the majority of patients with a Caucasian
background and in need of hematopoietic stem cell
transplants (HSCT) [1,2]. As a consequence, and
because of improved outcome [3], the number of unre-
lated donor transplants has steadily increased and ex-
ceeded for the first time in 2007 that of HLA-identical
sibling donor transplants in Europe [4]. Still, even
a well-matched unrelated donorHSCT remains associ-
ated with significant acute graft-versus-host disease
(aGVHD) or chronic graft-versus-host disease and
transplant-related mortality (TRM), and best unrelated
donor selection remains a matter of debate [5,6].
The implementation of HLA molecular typing in
the donor search process has clearly contributed to
Biol Blood Marrow Transplant 18:608-616, 2012 609HLA-DPB1 and Microsatellite Polymorphisms in Unrelated HSCTimprove the selection of optimally matched donors [1].
For many transplant centers, an HLA-A/B/C/DRB1/
DQB1-compatible (ie, 10 of 10 matched) donor is
considered as optimal with outcomes comparable to,
if not better than transplants from an HLA identical
sibling donor [5-8]. However, best outcome of
allogenic transplantation is observed with syngeneic
donors. TRM after an HSCT from an identical twin
donor is as low as, and the relapse rate is significantly
lower than, with autologous HSCT. Additional
matching for HLA-DPB1 should therefore in theory
improve outcome. However, previous studies on
the impact of DPB1matching have led to controversial
results [9-18]. An analysis of .5000 patients with
a myeloablative HSCT within the framework of
the 14th International Histocompatibility Workshop
(IHWS) showed that DPB1 incompatibilities
correlated with an increased risk of aGVHD and
a decreased disease relapse rate without any
significant impact on the probability of overall
survival (OS) [15]. The large National Marrow Donor
Program study was also unable to disclose an impact
on survival [16]. On the other hand, the Anthony
Nolan Research Center and the Japan Marrow Donor
Program studies reported that DPB1 disparities were
associated with decreased relapse risk [14,17] and
higher OS when acute leukemias patients were
analyzed separately [14]. More recent results showed
that the HLA-DPB1 compatibility did improve out-
come in patients with early-, but not late-stage leuke-
mia [18]. Still, explanations for these discrepancies
remain warranted.
Matching for all HLA loci includes compatibility
formajor histocompatibility complex (MHC)-encoded
non-HLA determinants in the family donor setting.
Blocks of DNA sequence variations form extended
haplotypes [19,21] that include the same HLA alleles
but also specific MHC-resident polymorphic markers.
These blocks of DNA sequence with linkage disequi-
librium may vary with and within the HLA haplotypes
but remain linked in a family donor setting. In contrast,
matching for all HLA loci does not necessarily imply
compatibility for these MHC-encoded non-HLA de-
terminants in the unrelated donor setting. They may
be associated with clinical outcome. Indeed, following
the initial investigations on polymorphic non-HLA
markers, the so-called MHC block matching [22],
a few studies have addressed the issue of matching for
non-HLA microsatellite polymorphisms (MPs) in the
MHC [23,24] and, more recently, for MICA alleles
[25] in unrelated HSCT. Using an elegant method to
separate the 2 haplotypes by microarray hybridization
with HLA-B allele-specific probes [26], Petersdorf
et al. [27] have shown that patient/donor haplotype
mismatching, that is, with HLA alleles not segregating
on the same chromosome, was associated with an
increased risk of aGVHD incidence.Because of the weaker linkage disequilibrium be-
tween the HLA-DRB1/DQB1 and the HLA-DPB1
loci [20], a large fraction of 10 of 10 allele matched
HSCT are performed across the HLA-DPB1 trans-
plantation barrier. Consequently, any evaluation of
the clinical impact of HLA-DPB1 compatibility
should also take into account the role of non-HLA
but MHC-linked polymorphisms. We therefore
hypothesized that such MPs could have an indepen-
dent and potentially divergent impact on outcome in
HLA-A/B/C/DRB1/DQB1-compatible (ie, 10 of 10
matched) unrelated donor HSCT. We made use
of the fact that all unrelated donor transplants in
Switzerland are mandatorily facilitated by the Founda-
tion Swiss Blood Stem Cells, that all donor recipient
pairs are retyped before transplant by the Swiss Na-
tional Reference Laboratory for Histocompatibility
in Geneva, and that pretransplantation donor and
recipient samples are stored for future analyses [2].
Results of this retrospective analysis on outcome of
HLA-DP1 and MPs within the MHC region form
the basis of this study.PATIENTS AND METHODS
Study Design
This was a retrospective analysis of 2 cohorts of
patients. The first cohort did include all 212 consecu-
tive patients transplanted with an HSCT from a 10 of
10matched unrelated donor between 2002 and 2008 in
Switzerland. Only 7 pairs for whom noDNAwas avail-
able to analyze HLA-DPB1 and MP were excluded
from the study. The second cohort comprised 34
patients transplanted from 1990 to 2002 who have
been DPB1-typed within the framework of the
IHWS [15]. These patients were only included in the
HLA-DPB1 analysis. Inclusion criteria for the total
of 246 patients for the final analysis were the availabil-
ity of patient and donor DNA samples and the updated
clinical data as of August 2009. The median follow-up
of surviving patients was 731 days (range: 88-1470).
Two-hundred forty-six patients were included in the
analysis of HLA-DPB1 MMs; 203 patients were
included in the MP analysis. The study has been ac-
cepted by the University Hospital of Geneva ethical
committee (No. 08-208R). All patients gave informed
consent to have their data reported to the Swiss Stem
Cell Transplant Group Database. Eighty-seven
consecutive patients transplanted (2002-2008) with
HSC from a #9/10 matched donor were not consid-
ered in this study.
Donor Search Algorithm and HLATyping
A standardized donor search algorithmwas used by
the National Reference Laboratory, the 4 transplant
centers, and the Foundation Swiss Blood Stem Cells
Table 1A. Patient Population, Clinical Characteristics
Values
Patients (n 5 246)
Male, n (%) 156 (63.4)
Female, n (%) 90 (36.6%)
Age, years (median, range) 39 (1-70)
Diagnosis
Acute leukemia, n (%) 112 (45.5%)
Chronic leukemia, n (%) 46 (18.7%)
MDS/MPS, n (%) 43 (17.5%)
Lymphoma, MM, n (%) 23 (9.3%)
Aplastic anemia, n (%) 7 (2.9%)
Other, n (%) 15 (6.1%)
Year of transplantation
1990-2001, n (%) 34 (13.8%)
2002-2005, n (%) 90 (36.6%)
2006-2008, n (%) 122 (49.6%)
Source of stem cells
Bone marrow, n (%) 81 (32.5%)
Peripheral blood, n (%) 163 (65.5%)
Cord blood, n (%) 2 (0.8%)
Transplant techniques
T cell depletion
Yes, n (%) 55 (23.3%)
No, n (%) 181 (76.7%)
Conditioning
Standard, n (%) 172 (70%)
Reduced, n (%) 71 (29%)
CMV status
Patient CMV-positive, n (%) 86 (47.5%)
Donor CMV-positive, n (%) 59 (32.8%)
EBMT risk score values
0 0
1 11 (4.5%)
2 46 (18.7%)
3 73 (29.7%)
4 53 (21.5%)
4 40 (16.3%)
6 21 (8,5%)
7 2 (0.8%)
MDS indicates myelodysplastic syndrome; MPS, myeloproliferative syn-
drome; CMV, cytomegalovirus.
Information on sex, stem cell source, conditioning, and year of trans-
plantation was missing for 3 patients, on T cell depletion for 9 patients,
and on CMV status for 68 patients and 69 donors.
610 Biol Blood Marrow Transplant 18:608-616, 2012F. Bettens et al.throughout the study period. Patients were classified
at the start of the search with a high, respectively,
intermediate and low probability estimate, based
on patients’ HLA haplotypes and on the donor HLA
phenotypes registered in bone marrow donor
worldwide as previously reported [2]. The high prob-Table 1B. Patient Population, HLA-DPB1, and MP
Genotyping
HLA-DPB1 Matching
0 mismatch (MM), n (%) 30 (12.2%)
1 MM, bidirectional, n (%) 93 (37.8%)
2 MM, n (%) 77 (31.3%)
1 MM, rejection direction, n (%) 32 (13%)
1 MM, GVH direction, n (%) 14 (5.7%)
MP genotyping
D6S510, n pat/n don 203/202
D6S265, n pat/n don 206/203
D6S2787, n pat/n don 208/208
D6S2789 (TNFd), n pat/n don 205/203
D6S2894, n pat/n don 208/210
D6S2749, n pat/n don 206/203ability estimates correlate with common/conserved
haplotypes, whereas the low probability estimates are
linked to less frequent haplotypes or to haplotypes
with uncommon associations or rare alleles [2].
Approximately 30% to 40% of the patients, mostly
classified with a high probability estimate at the start
of the search, had.1 potential 10 of 10 allele matched
donors. For these patients, final donor selection was
based on non-HLA criteria (age, sex, ABO,
cytomegalovirus [CMV]). All 246 patient/donor
pairs were matched at the allele level for the HLA-A,
-B, -C, -DRB1/B3/B5, -DQB1 loci by standard
methods (polymerase chain reaction (PCR)-
sequence-specific oligonucleotide on microbeads
arrays, PCR-sequence-specific primer, and sequence-
based typing). HLA-DPB1 disparities were analyzed
separately for their GVHD or rejection direction.
HLA-DPB1 permissive/nonpermissive MMs were as-
signed as described previously [28-30]. Briefly, for the
TCE3 (T cell epitope) algorithm, the patient and
donor DPB1 alleles were assigned in the following 3
groups: group 1 (DPB1*0901,*1001,*1701), group 2
(DPB1*0301,*1401,*4501), and group 3 (all other
DPB1 alleles). For the TCE4 algorithm, groups 1
and 2 were the same, the DPB1*02 alleles were
included as group 3, and group 4 consisted of all
other alleles. HLA-DPB1 MM were assigned as non-
permissive when any DPB1 allele belonging to groups
1 and 2 (TCE3) or groups 1, 2, and 3 (TCE4) was pres-
ent in the patient (graft-versus-host [GVH]) or donor
(host-versus-graft) only [30].
Patient Population
The 246 patients, 63% male, median age 39 years
(range: 1-70 years), were primarily treated for leuke-
mia (80%). The remainder suffered from lymphoma,
aplastic anemia, or other disorders as outlined in
Table 1A. About 23% had a low pretransplantation
risk profile by European Group for Blood andMarrow
Transplantation (EBMT) score (1-2), 30% intermedi-
ate (3), and 47% a high risk (4-7). In 72% a standard, in
29% a low-intensity conditioning was applied; about
one-quarter of the transplant products were T cell de-
pleted.
Genotyping of MPs
Genotyping of theMPD6S510 (25 kb centromeric
to HLA-A), D6S265 (100 kb centromeric to HLA-A),
D6S2787 (BAT2, 325 kb centromeric to HLA-B),
D6S2894 (NOTCH4, 350 kb telomeric to HLA-
DRB1), and D6S2749 (RING3CA, 125 kb telomeric
to HLA-DPB1) was performed according the the
13th IHWG protocol (http://www.ihwg.org/shared/
micros.hmt). PCR conditions for the primers
D6S510 (UniTS 480391), D6S265 (UniTS 256850),
D6S2787 (UniTS239131),D6S2894 (UniTS464327),
Table 2. Results of the Multivariate Analyses
Parameter OR 95% CI P
No common/conserved haplotype 1
Common/conserved haplotype 0.61 0.38-0.98 .04
Donor TNFd4/d5 absent 1
Donor TNFd4/d5 present 2.03 1.25-3.31 .004
0 DPB/1 MM rejection direction 1
1-2 DPB1 or 1 MM GVHD direction 1.77 1.03-3.04 .039
Patient D6S510-184 absent 1
Patient D6S510-184 present 0.44 0.22-0.87 .018
EBMT risk score
Score 1-2 1 .001
Score 3 2.26 1.03-4.95
Score 4 2.98 1.38-6.42
Score 5 5.16 2.32-11.49
Score $6 4.5 1.86-10.9
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all samples electrophoresed on an ABI3130 sequencer
using GeneMapper 4.0 software (Applied Biosystems,
Bedford, MA). The haplotype D6S265*176-
D6S2787*141-D6S2894*343 corresponds to the 180-
140-352 microsatellite genotype described by Malkki
et al. [31] that is strongly linked to the A1-B8-DR3
genotype. In a previous study, this microsatellite
genotype was confirmed in 129 A1-B8-DR3 individ-
uals [32]. The MP frequency profiles correspond
to those observed in previous studies [24-31]. For
the microsatellites D6S510, D6S265, D6S2787,
D6S2894, and D6S2749, the most frequent alleles
were allele 176 (31%), 176 (29%), 145 (29%),
340 (41%), and 225 (39%), respectively. The
microsatellite D6S2789, which corresponds to the
tumor necrosis factor d (TNFd) locus was analyzed
as described [33], using cell lines YAR (TNFd3),
AMALA (TNFd4), and WT51 (TNFd5) as controls.
For comparison purposes, patients and donors were al-
ways analyzed in parallel. TNFd4/d5 refers to the
presence of d4 and/or d5 allele.
Statistical Analyses
Frequencies ofMP alleles were calculated by direct
counting. To estimate aGVHD, the cumulative inci-
dence function was used with death from other causes
as GVHD defining the competing risk. To calculate
survival probabilities, the Kaplan-Meier estimator
was used with the log-rank test for comparisons among
groups. The Cox regression model was used for multi-
variate analysis, including genotyping results (con-
served haplotype, HLA-DP1 matching, and MPs),
disease, clinical pretransplantation risk factors, treat-
ment variables (T cell depletion, conditioning inten-
sity), and year of transplantation. For the clinical
pretransplantation risk factors, we made use of the
EBMT risk score, which includes patient age, disease
stage, donor type, donor-recipient sex-matching, and
time from diagnosis to transplantations, as decribed
in Table 2 of ref. [34].RESULTS
Common/Conserved Haplotypes and Outcome
Probability of OS was significantly better in 107
patients assigned to the high probability category
(common and conserved HLA haplotypes) with a 5-
year survival rate of 55% 6 18% compared with
39% 6 18% in 103 patients with a low/intermediate
probability assignement (uncommon haplotypes) as
shown in Figure 1A (P 5 .021). The multivariate
Cox regression analysis confirmed the lower risk of
death for patients with a common/conserved haplo-
type with a relative risk 0.62 compared with patients
without such haplotypes (confidence interval [CI]
0.39-0.98, P 5 .04).DPB1 Incompatibilities and GVHD and OS
A total of 26 different alleles were detected among
the 246 donor recipient pairs (492 individuals). Five al-
leles (DPB1*01:01, *02:01, *03:01, *04:01, *04:02) oc-
curred at a frequency.5%, with DPB1*04:01 present
in .40% of the individuals. This corresponds to the
data from the published heterogenous IHWS cohort
of 5929 patients, although with slightly different fre-
quencies. Allele frequency distribution did not signifi-
cantly differ between the patient and donor groups. Of
the 246 pairs, 30 (12.2%) shared complete DPB1 com-
patibility, which is comparable to the rate observed in
the French [12], Austrian [13], and IHWS [15] studies,
but lower compared with the 29%DPB1 compatibility
rate reported in the Anthony Nolan study [14]. Bidi-
rectional MMs occurred in 69.2% of the pairs, 1 MM
in the GVH direction in 5.7% and in the rejection
direction in 13% of the pairs (Table 1B). The ratios
of DPB1-matched recipient/donor pairs were similar
in categories with or without common/conserved
haplotypes (12% and respectively 14%; cohort of
212 patients).
The impact of DPB1 MM was first analyzed by
computing the cumulative incidence of grade II-IV
GVHD (Figure 1B). The results showed a GVHD in-
cidence of 18% (CI 8%-40%) for 0MM patients, 46%
(CI 38%-54%) for 1-2 MM patients, 25% (CI 13%-
47%) for patients with 1 MM in rejection direction,
and 50% (CI 28%-88%) for patients with 1 MM in
the GVH direction (P 5 .014). Kaplan-Meier esti-
mates of 5-year OS showed a beneficial effect of
DPB1 matching with a 71 6 12% survival rate in the
0 MM and 1 MM rejection direction versus 48 6
10% in the 1-2 DPB1 MM and 1 MM in the GVH di-
rection pairs (P5 .036) (Figure 1C). The multivariate
Cox regression analysis confirmed the higher risk of
GVHD for patients with DPB1 disparities (odds ratio
[OR] 5 3.8; CI 1.46-9.85; P 5 .005) (Figure 1B).
The ratios of permissive/nonpermissive MMs ac-
cording to the T cell epitope 3 (TCE3) [28,29] and
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Figure 1. Impact of HLA haplotype, HLA-DPB1 and MHC-linked microsatellite polymorphisms on outcome after HLA-A/B/C/DRB1/DQB1-
compatible unrelated donor HSCT. (A) Impact of common/conserved haplotype on OS after 10/10 HLA allele matched unrelated donor HSCT. Com-
mon/conserved haplotype (high probability category) 107 patients, noncommon/conserved haplotype (low/intermediate category) 103 patients. For
definitions, see [2]. (B) Cumulative incidence of significant aGVHD (grade II-IV) according the HLA-DPB1 matching status (see Table 2). 0 MM corre-
sponds to a 12 of 12 antigen matched donor recipient pair, 1-2 MM includes 10-11 of 12 antigen matched pairs (bidirectional MM), 1 MMGVHD includes
11 of 12 antigen matched pairs with a DP1 MM in the GVHD direction only, 1 MM rej includes 11 of 12 matched pairs with a DPB1 mismatch in rejection
direction only. (C)OS according toDPB1matching status (see Table 2). 0 MM, 1MM rej includes 12 of 12 antigenmatched donor recipient pairs and 11 of
12 antigen matched pairs with a DPB1mismatch in the rejection direction. 1-2 MM bi and 1 MMGVHD includes 10 of 12 antigen matched pairs and 11 of
12 antigen matched pairs with a DPB1 mismatch in the GVHD direction. (D) Kaplan-Meier OS estimates in 10 of 10 matched patients by combining
donor DPB1 matching status and TNFd4/d5 genotype. Patients transplanted with a DPB1-mismatched and TNFd4/d5-positive donor (56 of 203, lower
curve) show a highermortality comparedwith patients transplantedwith a DPB1matched/1DPB1MM rejection only and a d4/d5-negative donor (upper
curve, 31 of 203) (OS: 28% versus 72%, P5.001). TNFd4/d5 alone (21 of 203) andDPB1mismatching alone (95 of 203) had less of an impact (60%6 28%
and 55% 6 20%, respectively, intermediate curves).
612 Biol Blood Marrow Transplant 18:608-616, 2012F. Bettens et al.TCE4 [30] algorithms in the 216 patients with DPB1
incompatibilities were similar to those published pre-
viously. The TCE3 algorithm revealed no survival dif-
ference between permissive and nonpermissive MM
compared with the 0 MM group (data not shown).
However, using the TCE4 algorithm, nonpermissive
MM seemed to result in a slightly lower survival prob-
ability (49% 6 10%) compared with permissive MM
(56% 6 18%) and to the 0 MM group (69% 6
19%), but the difference was not statistically signifi-
cant (data not shown).MHC-Resident MPs and Survival
Differences in MPs between donor and recipient
showed no correlation with OS for any of the tested
loci. Patients were then classified according the total
number of MM at all MPs. There was no detectableeffect of MP matching or mismatching by analyzing
patients with 0-1 MM, 2-3 MM, and $4 MM, respec-
tively (data not shown).
The analysis of the most frequent alleles at each
microsatellite locus allowed us to identify alleles with
an association with OS (Figure 2). Effects were differ-
ent on outcome. D6S510-184 allele was associated
with a higher survival rate at 5 years when present in
the patients (74 6 14% versus 43 6 13%, P 5 .01)
and, although not significant, in the donor (70% 6
16% versus 46% 6 13%, P 5 .075). In contrast, the
donor D6S265-182 allele was associated with de-
creased survival (21 6 31% versus 60% 6 10%, P 5
.053). Similarly, the donor D6S2749-231 allele in the
class II region was associated with decreased survival
(40%6 15% versus 57%6 16%, P5 .02). In the class
III region, TNFd4/d5 alleles were associated with de-
creased survival. Effects were observed with TNFd4
A DPDR/DQC B
D6S265 D6S2787 D6S2894
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Figure 2. MHC-resident MPs and survival. The 6 MP loci analyzed in this study are schematically represented on the HLA region with the total number
of alleles detected in this patient and donor cohort. Three genotypes were significantly associated with OS. Presence of TNFd4 and/or d5 MP alleles in
patient (80 of 205) (P5.007) or donor (77 of 203) (P5.003) was associated with lower survival compared with TNFd4/d5-negative patient/donor pairs.
Donor MP D6S2749-231 allele (72 of 203) was also associated with lower OS (P 5 .02). Patient (46 of 203) and donor (40 of 202) D6S510 were
associated with lower mortality risk (P5 .01 and P5 .075, respectively). The association of D6S265-182 with lower survival is of borderline significance
(P 5 .053).
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(37% 6 15% versus 60% 6 15%, P 5 .003) as well
as with TNFd4/d5-positive patients (41%6 14% ver-
sus 58%6 16%, P5 .007). No significant correlation
with OS could be observed with the D6S2787 and
D6S2894 alleles.0
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Figure 3. Survival probability for each EBMT risk score category as
a function of the 2 donor-associated genetic risks, HLA-DPB1 MM
and/or TNFd4/d5. Survival probability at 5 years by EBMT risk score,
with low-risk (no DP mismatch, TNFd4/d5-negative, diamonds),
intermediate-risk (either DP mismatch or TNFd4/d5-positive, squares),
or high-risk genetic factors (DP mismatch and TNFd4/d5-positive, trian-
gles). Having 1 or 2 of the genetic risk factors conferred an increased risk
of mortality for each of the 3 EBMTrisk score groups.Multivariate Analysis
The Cox regression model confirmed the predic-
tive value of the EBMT risk score (Table 2) as an inter-
nal standard of the analysis with decreasing survival
with increasing risk score. It showed that patients
with a common/conserved haplotype had a signifi-
cantly lower mortality risk (P 5 .04). DPB1 MMs
(P 5 .039) as well as TNFd4/d5 donor genotype
(P5 .004) were significantly associated as independent
variables with decreased survival, whereas patient
D6S501-184 was significantly associated with in-
creased OS (P 5 .018) (Table 2).
The effects of DPB1 MM and MPs appeared to
be additive onOS.There was a significant and stepwise
impact of combined DPB1 MM and TNFd4/d5
on survival: 5-year survival decreased from 72% 6
18% for patients transplanted with HSCT from
a DPB1-matched and TNFd4/d5-negative donor,
60% 6 28% and 55% 6 20%, respectively, for pa-
tients with TNFd4/d5 or DPB1 mismatching alone,
to 28%6 16% (P5 .001) for patients with the combi-
nation of DPB1 MM and TNFd4/d5 polymorphism(Figure 1D). The 2 MHC-linked genetic donor
factors, DPB1 MM (75% of patients; Table 1B) and
TNFd4/d5 genotype (38% of patients, Figure 1D),
acted additive to the EBMT risk score with a stepwise
reduction in survival in all risk categories (hazard ratio
[HR] 5 2.97; CI 1.27-6.92; P 5 .012) (Figure 3).
When GVHD incidence was computed by taking
into account the presence of DPB1 MMs and/
or the TNFd4/d5 genotypes, the results showed a sim-
ilar incidence in the patients transplanted with
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(39%, CI 27%-56%), as in patients transplanted with
a DPB1-mismatched or TNFd4/d5-positive donor
(41%, CI5 31%-52%) (data not shown). Thus, no ad-
ditive effect of DPB1 incompatibility and TNFd4/d5
genotype could be detected with respect to GVHD in-
cidence. This lack of an additive effect of TNFd4/d5
genotype could possibly be related to the low percent-
age of TNFd4/d5-positive/DPB1 matched donors
compared with that of DPB1 mismatched/TNFd4/
d5-negative donors (18% versus 82%). However,
TRM was higher in patients with a DPB1 mismatched
andTNFd4/d5-positive donor compared with patients
with a DPB1 mismatched or a TNFd4/d5-positive
donor (33.9% versus 21.6%) and to patients with
a ‘‘no DPB1 MM/no TNFd4/d5’’ donor (6.5%)
(P 5 .006, data not shown). In contrast, relapse rates
were similar in patients with a DPB1 mismatched
and TNFd4/d5-positive donor and in patients with
DPB1 matched/TNFd4/d5-negative donor (17.9%
and 16.1%, respectively, data not shown).DISCUSSION
This study confirms and expands previous findings
and sheds light on some of the controversies sur-
rounding the role of HLA-DPB1 in allogeneic
unrelated HSCT [9-19,35]. HLA-DPB1, several
MHC-resident non-HLA polymorphisms, and a con-
served/common haplotype were identified in this con-
secutive cohort of 246 patients as relevant risk factors
for outcome after unrelated donor HSCT. These
risk factors were independent from each other and
added to the key clinical pretransplantation risks as
represented by the EBMT risk score [34].
Patients with more common/conserved haplo-
types, that is, those with a high probability estimate
[2], did have a higher survival probability compared
with patients with less frequent/conserved haplotypes.
This effect was independent of the DPB1mismatching
rate and of the other MHC-resident polymorphisms
tested. The study showed a significant impact of
DPB1 disparities in GVH direction on aGVHD inci-
dence and a significant impact of 12/12 matched
patients on survival. This beneficial effect of DPB1
matching was independent of the common/conserved
haplotype effect as shown by the multivariate analysis.
Last, the study showed a clear effect of MHC linked
microsatellite polymorphisms on outcome. These
effects were not due to a MM in this region between
donor and recipient but to the specific polymorphism
itself. The microsatellite loci are located respectively
100 kb from the A-locus, in the class III region
(TNFd), and 125 kb from HLA-DPB1. Some of these
loci were associated with increased, others with de-
creased survival. These effects were independent of
DPB1 matching, independent of common or uncom-mon haplotype, and acted additive to clinical risk fac-
tors. This was probably the most important finding.
The observation of better survival with common/
conserved haplotypes is in line with the haplotype mis-
matching effect on aGVHD incidence described previ-
ously [27]. It is relevant to note that rare haplotypes
including B*51:01, B*18:01, or B*15:01 that are more
frequently mismatched at C-locus show a lower link-
age disequilibrium compared with B*08:01 or
B*07:02 haplotypes [19]. Indeed, Caucasoid patients
with 1 or 2 common haplotypes showed a slightly
higher rate of haplotype matching (78%-80%) com-
pared with patients with no common haplotypes
(71%) [27].We can speculate that the uncommon hap-
lotypesmight exhibitmore diversity in non-HLApoly-
morphisms. The results of a recent study on 1810 10 of
10 matched HSCT patients regarding occurence of
aGVHD among 3 of the most conserved haplotypes
in the Japanese population support this assumption
[35]. Not tested was the possibility that the common
haplotypes alone were responsible for the better out-
come. The independent effect of some haplotypes on
outcome was recently shown by a Japanese study [35].
The impact on survival with TNFd4/d5-negative
donors compared with TNFd4/d5-positive donors
and positive recipients validates our previous analysis
[33] in a second completely independant cohort. The
data are concordant with the results of Keen et al.
[36], who showed a higher risk of TRM in TNFd4-
positive partially matched unrelated HSCT patients,
and with 2 studies [37,38] reporting a higher GVHD
risk linked to the TNFd4 genotype in partially
matched unrelated HSCT cohorts. In our study,
incompatibility at the DPB1 locus and TNFd4/d5
genotype appear to provide additive affects on TRM,
which does clearly impact on OS (Figures 1D and 3).
However, no impact on relapse rate was disclosed,
although the patient groups were small.
We considered the possibility that OS differences
between the common/conserved versus uncommon
categories could at least partly be accounted for by
an increased frequency of the TNFd4 and d5 alleles
in haplotypes with higher allelic variations. Indeed,
TNFd4/d5 alleles occured more frequently in
B*51:01- and B*15:01-positive individuals who are
known to be more frequently HLA-C incompatible.
However, multivariate analysis showed that the effect
of common/conserved haplotype was independant of
the microsatellite alleles analyzed. Therefore, the clas-
sification in high versus low/intermediate probability
estimates must contain additional genetic information
not captured by the MP analysis. Such genetic infor-
mation may be linked to the ‘‘haplotype mismatching’’
effect [27] based on the segregation of the same A, B,
DRB1 alleles on different haplotypes. Hence, these
specific microsatellite alleles may serve as surrogate
markers for other non-HLA polymorphisms that
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response to infections. TNFd locus, as an example, is
located in intron 4 of the leucocyte-specific tran-
script-1 gene with a presumed immunoregulatory
function [39]. However, the independent role of
DPB1 matching and 3 MPs shown on survival in mul-
tivariate analysis rejects the hypothesis that all of the
effect of the frequent/conserved haplotype (high ver-
sus low matching probability) could be explained by
these polymorphisms.
Most important, the data from this study showed
that the examined genetic risk factors, conserved hap-
lotype, DPB1, andMPs all acted additive to each other
and as well additive to the key clinical pretransplanta-
tion risk factor, the EBMT risk score. This risk score
was recently shown to be valid for all acquired hemato-
logic disorders and in autologous and allogeneic
HSCT. Integration of the EBMT risk score into the
multivariate analysis permits assessment across a het-
erogeneous patient population. Unfavorable genetic
risk factors decreased survival in addition to the risk
score. A similar effect has recently been observed in re-
lated HSCT for chronic myeloid leukemia with
TNFRSFIB, interleukin-10, and IL1RN polymor-
phisms [40]. Altogether, these data point to an HLA
haplotype effect that sums up the impact of multiple
HLA and non-HLA loci extending over the entire
HLA region. Numbers in our series were too low to
determine precisely whether the effects of these ge-
netic factors were more marked in clinically low- or
high-risk patients as has been recently suggested by
an analysis on DPB1 where survival was better with
matching in low-risk leukemias, and better with mis-
matching in high-risk leukemias [18].
What are the consequences of this report? Clearly,
future analyses on effects of HLA antigens should
include other relevant MHC-linked MPs. Their addi-
tive or divergent effects on survival could hide effects
of the respective HLA antigens as well. Second, the
search for HLA-DPB1 and relevant MHC-linked
MPs should be integrated into the donor search algo-
rithm for those 30% to 40% patients with several 10 of
10 antigens matched donors identified and early leuke-
mia [6,41-42]. In an unselected group of patients with
a 10 of 10 matched donor, 25% are expected to be
DPB1 matched (0 MM or 1 MM in rejection
direction) (Table 1B), and 60% of these donors are ex-
pected to be TNFd4/d5-negative (Figure 1D). By test-
ing 2 to 3 additional donors for each patient with
common haplotypes (high probability searches), it
should therefore be possible to identify a DPB1-
matched and TNFd4/d5-negative donor for about
20% to 30% of patients. This might imply changes
in donor search strategies, and might also impact on
typing strategies in donor registries by including
HLA-DPB1 testing on the most frequent HLA-A, B,
C, DRB1 haplotypes.ACKNOWLEDGMENTS
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